Last reviewed · How we verify
LY2216684 (edivoxetine)
LY2216684 (edivoxetine) is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system.
LY2216684 (edivoxetine) is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system. Used for Attention-deficit/hyperactivity disorder (ADHD).
At a glance
| Generic name | LY2216684 (edivoxetine) |
|---|---|
| Also known as | LY2216684, edivoxetine |
| Sponsor | Eli Lilly and Company |
| Drug class | Selective norepinephrine reuptake inhibitor (NRI) |
| Target | Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Edivoxetine works by blocking the reuptake of norepinephrine at the presynaptic neuron, thereby increasing norepinephrine concentration in the synaptic cleft. This mechanism is thought to enhance attention, focus, and executive function. The drug was developed for attention-deficit/hyperactivity disorder (ADHD) and other conditions where noradrenergic dysfunction plays a role.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
Common side effects
- Insomnia
- Headache
- Nausea
- Increased heart rate
- Elevated blood pressure
Key clinical trials
- A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder (PHASE2, PHASE3)
- A Study of LY2216684 in Healthy Participants (PHASE1)
- A Study of LY2216684 in Participants With Major Depression Disorder (PHASE3)
- A Study of LY2216684 in Participants With Impaired Hepatic Function (PHASE1)
- A Study for Participants With Major Depression (PHASE2)
- A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor (PHASE3)
- A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment (PHASE3)
- A Study in Prevention of Re-emergence of Depression Symptoms (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2216684 (edivoxetine) CI brief — competitive landscape report
- LY2216684 (edivoxetine) updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI